Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943033 | 0.95 | EPAS1 (0.33) | HTR2CCCR5 | |
| SCHEMBL10149928 | 0.93 | EPAS1 (0.32) | HTR2C | |
| SCHEMBL17733612 | 0.93 | EPAS1 (0.32) | HTR2C | |
| SCHEMBL4129266 | 0.86 | MBTD1 (0.36) | — | |
| SCHEMBL13351747 | 0.86 | MBTD1 (0.36) | — | |
| SCHEMBL16877663 | 0.85 | — | — | |
| SCHEMBL433801 | 0.84 | SLC6A1 (0.34) | HTR2C | |
| SCHEMBL23373293 | 0.83 | HTR2C (0.32) | HTR2C | |
| SCHEMBL20121932 | 0.83 | CXCR4 (0.31) | — | |
| SCHEMBL5680966 | 0.82 | EPAS1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | TEIJIN, LIMITED (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1477490-A1 | PYRROLOPYRIMIDINE DERIVATIVE | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | HTR2C 4543/4885CCR5 2645/4885 |
| US-20050171094-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | HTR2C 2734/4885CCR5 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.